ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?

Liang, Xieer; Xie, Qing; Shang, Jia; Tang, Hong; Xu, Min; Meng, Qinghua; Zhang, Jiming; Gao, Pujun; Sheng, Jifang; Wang, Hao; Jia, Jidong; Wang, Guiqiang; Wu, Shunquan; Ping, Jingna; Hou, Jinlin*复旦大学; 北京大学; 吉林大学; 南方医科大学; 四川大学; 浙江大学; 1
Journal of Gastroenterology and Hepatology2022-3DOI: 10.1111/jgh.15757
6阅读
引用收藏
分享

摘要

Background and Aim Tenofovir disoproxil fumarate (TDF) is a first-line treatment for chronic hepatitis B virus (HBV) infection for its high potency and a low rate of drug resistance. This study investigated the efficacy and safety of TDF in Chinese patients with chronic hepatitis B (CHB) infection after treatment failure with multiple nucleos(t)ide analogues (NAs). Methods Patients included were aged 18-65 years, with treatment failure with multiple NAs (serum HBV DNA > 200 IU/mL after more than two different NA treatments). The primary endpoint was proportion of patients with serum HBV DNA Overall, 213 patients were enrolled. At Week 144, mean HBV DNA decreased significantly from baseline (4.4 vs 1.4 log(10) IU/mL), with 77.0% patients (95% confidence interval: 71.1, 82.9) achieving serum HBV DNA < 20 IU/mL. Three (1.4%) patients experienced virological breakthrough during TDF monotherapy, without hepatitis flare. At Week 144, 15.3% and 4.7% patients (hepatitis B e antigen [HBeAg]-positive at baseline) experienced HBeAg loss and HBeAg seroconversion, respectively; 68.3% patients achieved normalized alanine aminotransferase levels. Overall, 58.7% patients experienced more than one adverse event (AE). Most common AEs were upper respiratory tract infection and blood creatine phosphokinase increase; 8.5% patients experienced study drug-related AEs; 9.4% patients experienced serious AEs (none were TDF-related). Among renal safety parameters, overall trend of mean serum phosphorous level remained stable, while mean estimated glomerular filtration rate increased slightly. Conclusions Tenofovir disoproxil fumarate monotherapy is efficacious in CHB patients with multiple NAs treatment failure with no new safety findings.

学科与关键词

关键词
antiviral resistanceChinaefficacyhepatitis B e antigenhepatitis B surface antigenhepatitis B virushepatitis B virus resistancemultidrug-resistancesafetyvirological response
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Gastroenterology and Hepatology
发表日期
2022-03
卷期
第 37 卷, 第 3 期
页码
471-479
DOI
10.1111/jgh.15757
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
GlaxoSmithKline (China) R&D Company Limited; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]

作者

  • L

    Liang, Xieer (第一作者)

    southern med univ

  • X

    Xie, Qing

    ruijin hosp

查看全部 15 位作者收起作者
  • S

    Shang, Jia

    henan prov peoples hosp

  • T

    Tang, Hong

    sichuan univ

  • X

    Xu, Min

  • M

    Meng, Qinghua

  • Z

    Zhang, Jiming

    fudan univ

  • G

    Gao, Pujun

    jilin univ

  • S

    Sheng, Jifang

    1 · zhejiang univ

  • W

    Wang, Hao

    peking univ

  • J

    Jia, Jidong

    capital med univ

  • W

    Wang, Guiqiang

    peking univ

  • W

    Wu, Shunquan

  • P

    Ping, Jingna

  • H

    Hou, Jinlin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417